Shots:

• Regeneron to receive a $30M up front and is eligible to receive ~$63M in regulatory and sales milestones & will be responsible to commercialize Evkeeza in the US
• Ultragenyx get the rights to develop & commercialize the product in countries outside of the US for HoFH & other indications & will be responsible to share costs for trials
• Ultragenyx also gets an exclusive option to develop and commercialize outside of the US which is currently in a P-II/III trial for the treatment of the ultra-rare disease & FOP. Evkeeza is a fully human mAb that binds & blocks ANGPTL3 function

Ref: PR Newswire | Image: Times Union